Project Grant R21AG087361
Award Date
4/15/24
Completion Date
3/31/26
Dollars Obligated
$461K
Federal Agency
National Institute on Aging
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) provides $842,114 to the Icahn School of Medicine at Mount Sinai to systematically investigate the molecular mechanisms of brain senescence in different Alzheimer's disease (AD) subtypes. The goal is to identify novel targets and develop therapeutics for AD. The multi-disciplinary research team will use a comprehensive "senome" profiling pipeline to...
The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $1,684,689 project grant to Weill Medical College of Cornell University to study the role of microglial lysosomes in the degradation of amyloid-beta, a key pathological feature of Alzheimer's disease. The 3-year project aims to characterize the process of "digestive exophagy" used by microglia to limit the expansion of amyloid-beta plaques, as well as explore the effects of genetic...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $442,357 aims to elucidate the molecular mechanisms underlying the neurodegenerative reprogramming of microglia, the brain's primary immune cells, in Alzheimer's disease (AD). The key research objectives are to: 1) determine the mechanisms by which the Integrated Stress Response (ISR) pathway triggers chromatin remodeling in microglia, 2) test whether ISR exacerbates stressed microglia...
This $903,172 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to examine the role of clonal somatic mutations in microglia and their contribution to the development of Alzheimer's disease (AD). The key objectives are to: Identify somatic mutations by re-analyzing existing bulk RNA-sequencing datasets from large AD cohorts, comparing the burden and distribution of somatic mutations between AD patient and control brain regions. Conduct...
This $1,425,000 project grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into neuronal senescence and inflammation in Alzheimer's disease. The Salk Institute for Biological Studies will study the interaction between cellular senescence and inflammation in induced neurons derived from Alzheimer's patients and healthy aged controls. Researchers will examine differences in gene expression and epigenetic...
The National Institute on Aging (NIA) awarded a Project Grant of $1,473,241 under the Aging Research Federal Grant Program (CFDA 93.866) to Mayo Clinic to investigate the role of adipose senescent cells in cognitive function and Alzheimer's disease progression. The grant, running from August 15, 2024 to May 31, 2029, aims to determine how the aging- or obesity-driven accumulation of senescent cells in adipose tissue may contribute to cognitive decline and neurodegeneration through endocrine...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This $614,424 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to better understand the role of microglia, the brain's immune cells, in the progression of Alzheimer's disease (AD). The University of Washington is the prime awardee and will leverage novel explainable AI techniques and human-induced pluripotent stem cell (iPSC) models to uncover subtle microglial changes occurring early in AD. Specific objectives include using AI to identify...
This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $842,175 to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA, to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies. The project aims to assess the therapeutic efficacy of a novel NOX2 inhibitor, GSK2795039, in mitigating AD-related brain dysfunction, including A-induced neuropathology, transcriptomic...